Mercier Johanna insider trades
Mercier Johanna has filed 58 Form 4s with the SEC that we hold, for Gilead Sciences, INC. (GILD) (Chief Comm & Corp Aff Officer) and Neurocrine Biosciences INC (NBIX) (Director). Across all of them we count 0 purchases worth $0 and 40 sales worth $29.7M reported on Form 4. In the last 12 months: 0 purchases ($0) and 23 sales ($18.6M). The largest single trade was a sale of 25,524 shares of Gilead Sciences, INC. worth $3.2M, dated 2025-11-17. Of 4 sales filed since we began reading the 10b5-1 checkbox, 4 (100%) were marked as made under a 10b5-1 trading plan. The first filing on our record is dated 2021-07-27 and the latest 2026-10-16.
Gilead Sciences, INC. (GILD)
| Trade date | Code | Shares | Value as filed | Filed | Source |
|---|---|---|---|---|---|
| 2024-01-09 | S, sale reported on Form 4 | 8,242 | $702.5K | 2024-01-10 | SEC |
| 2024-08-13 | S, sale reported on Form 4 | 5,490 | $406.2K | 2024-08-14 | SEC |
| 2024-08-28 | S, sale reported on Form 4 | 9,513 | $742.3K | 2024-08-29 | SEC |
| 2024-09-12 | S, sale reported on Form 4 | 15,925 | $1.3M | 2024-09-13 | SEC |
| 2024-09-12 | S, sale reported on Form 4 | 13,432 | $1.1M | 2024-09-13 | SEC |
| 2024-11-06 | S, sale reported on Form 4 | 5,000 | $456.4K | 2024-11-07 | SEC |
| 2025-05-22 | S, sale reported on Form 4 | 12,500 | $1.3M | 2025-05-23 | SEC |
| 2025-05-22 | S, sale reported on Form 4 | 3,000 | $322.6K | 2025-05-23 | SEC |
| 2025-06-16 | S, sale reported on Form 4 | 3,000 | $330.5K | 2025-06-17 | SEC |
| 2025-07-15 | S, sale reported on Form 4 | 3,000 | $333.1K | 2025-07-16 | SEC |
| 2025-08-15 | S, sale reported on Form 4 | 2,800 | $331.8K | 2025-08-18 | SEC |
| 2025-08-15 | S, sale reported on Form 4 | 200 | $23.8K | 2025-08-18 | SEC |
| 2025-08-15 | S, sale reported on Form 4 | 700 | $83.3K | 2025-08-18 | SEC |
| 2025-08-15 | S, sale reported on Form 4 | 11,800 | $1.4M | 2025-08-18 | SEC |
| 2025-08-15 | S, sale reported on Form 4 | 11,800 | $1.4M | 2025-08-18 | SEC |
| 2025-09-15 | S, sale reported on Form 4 | 3,000 | $340.7K | 2025-09-16 | SEC |
| 2025-10-15 | S, sale reported on Form 4 | 3,000 | $354.2K | 2025-10-16 | SEC |
| 2025-11-17 | S, sale reported on Form 4 | 2,476 | $312.6K | 2025-11-18 | SEC |
| 2025-11-17 | S, sale reported on Form 4 | 25,524 | $3.2M | 2025-11-18 | SEC |
| 2025-12-15 | S, sale reported on Form 4 | 3,000 | $366.0K | 2025-12-16 | SEC |
| 2026-01-15 | S, sale reported on Form 4 | 3,000 | $372.9K | 2026-01-16 | SEC |
| 2026-02-17 | S, sale reported on Form 4 | 18,405 | $2.8M | 2026-02-18 | SEC |
| 2026-02-17 | S, sale reported on Form 4 | 9,395 | $1.5M | 2026-02-18 | SEC |
| 2026-02-17 | S, sale reported on Form 4 | 200 | $31.1K | 2026-02-18 | SEC |
| 2026-03-16 | S, sale reported on Form 4 | 3,000 | $432.7K | 2026-03-17 | SEC |
| 2026-04-15 | S, sale reported on Form 4 | 3,000 | $422.9K | 2026-04-16 | SEC |
| 2026-05-15 | S, sale reported on Form 4 | 700 | $92.9K | 2026-05-18 | SEC |
| 2026-05-15 | S, sale reported on Form 4 | 11,177 | $1.5M | 2026-05-18 | SEC |
| 2026-05-15 | S, sale reported on Form 4 | 8,374 | $1.1M | 2026-05-18 | SEC |
| 2026-05-15 | S, sale reported on Form 4 | 7,749 | $1.0M | 2026-05-18 | SEC |
| 2026-06-15 | S, sale reported on Form 4 | 1,480 | $182.7K | 2026-06-16 | SEC |
| 2026-06-15 | S, sale reported on Form 4 | 450 | $56.4K | 2026-06-16 | SEC |
| 2026-06-15 | S, sale reported on Form 4 | 1,070 | $132.7K | 2026-06-16 | SEC |
| 2026-07-15 | S, sale reported on Form 4 | 3,000 | $389.8K | 2026-07-16 | SEC |
| 2026-08-17 | S, sale reported on Form 4 | 16,530 | $2.3M | 2026-08-18 | SEC |
| 2026-08-17 | S, sale reported on Form 4 | 11,470 | $1.6M | 2026-08-18 | SEC |
| 2026-09-15 | S, sale reported on Form 4 | 1,600 | $229.9K | 2026-09-16 | SEC |
| 2026-09-15 | S, sale reported on Form 4 | 800 | $115.6K | 2026-09-16 | SEC |
| 2026-09-15 | S, sale reported on Form 4 | 600 | $87.2K | 2026-09-16 | SEC |
| 2026-10-15 | S, sale reported on Form 4 | 3,000 | $468.7K | 2026-10-16 | SEC |
Neurocrine Biosciences INC (NBIX)
No purchase or sale of common stock reported here; these filings cover grants, option exercises or other codes.
Counted from the Form 4 filings this reporting owner (SEC CIK 1782135) filed on EDGAR. Values are the transaction values as filed. See every filing on EDGAR, or browse insider buying and today's insider purchases.
